Mijten Bencard (Dermatophagoides Farinae)

Dermatophagoides farinae, the active ingredient in Mijten Bencard, is an allergen extract presented as a cutaneous preparation for subcutaneous administration. It is indicated for the treatment of allergic rhinitis and allergic asthma that result from sensitisation to Dermatophagoides farinae, helping to reduce symptom severity and improve quality of life in affected individuals.

GNH USA supplies Mijten Bencard as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide with adherence to quality standards and regulatory requirements.

Mijten Bencard is used in allergen immunotherapy to modify the immune response to house dust mite allergens.

Allergic rhinitis: reduces nasal congestion, sneezing and itching by inducing tolerance to Dermatophagoides farinae. Allergic asthma: improves lung function and decreases exacerbations through modulation of allergen‑specific IgE. Sensitisation to Dermatophagoides farinae: helps prevent progression of allergy by building long‑term immunological tolerance.

Mijten Bencard may cause local and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site redness: mild erythema at the administration site. - Swelling: transient local edema. - Itching: pruritus around the injection area. - Transient wheeze: brief mild respiratory wheezing that resolves without intervention.

Serious or Rare Side Effects: - Anaphylaxis: severe systemic allergic reaction requiring immediate medical attention. - Systemic asthma exacerbation: worsening of asthma symptoms after dosing. - Serum sickness‑like reaction: fever, rash and arthralgia occurring days after administration. - Severe urticaria: widespread hives that may indicate a systemic response.

Before prescribing Mijten Bencard, consider the following precautions to ensure safe use.

Pregnancy: safety has not been established; use only if potential benefit justifies the risk. Breastfeeding: unknown excretion in milk; caution is advised. Severe uncontrolled asthma: contraindicated due to risk of systemic reactions. Concurrent immunotherapy: avoid simultaneous administration of other allergen extracts. Monitoring: observe patients for at least 30 minutes after injection for signs of systemic allergy. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mijten Bencard can interact with certain medications, influencing the risk of allergic reactions or therapeutic efficacy.

Major Interactions (Avoid): - Beta‑blockers: may potentiate anaphylactic responses and hinder treatment. - ACE inhibitors: can increase the likelihood of severe hypotension during systemic reactions. - Immunosuppressants: may diminish the immunomodulatory effect of the extract.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of systemic reactions, requiring careful observation. - Corticosteroids: can alter immune response, potentially affecting treatment outcomes. - Other allergen extracts: combined use may raise cumulative allergen load and reaction risk.